National Pension Service Has $17.04 Million Holdings in United Therapeutics Corporation $UTHR

National Pension Service boosted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 29.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,644 shares of the biotechnology company’s stock after acquiring an additional 9,202 shares during the period. National Pension Service owned approximately 0.09% of United Therapeutics worth $17,038,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. CWM LLC lifted its holdings in shares of United Therapeutics by 204.3% during the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after purchasing an additional 3,487 shares in the last quarter. AXQ Capital LP raised its holdings in United Therapeutics by 495.4% during the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after buying an additional 3,235 shares during the period. Great Lakes Advisors LLC lifted its stake in United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after buying an additional 2,975 shares in the last quarter. Osaic Holdings Inc. lifted its stake in United Therapeutics by 271.0% in the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock valued at $14,027,000 after buying an additional 33,662 shares in the last quarter. Finally, Simplify Asset Management Inc. acquired a new position in shares of United Therapeutics in the third quarter valued at approximately $8,351,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on UTHR. HC Wainwright raised their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company lifted their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada increased their price objective on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $509.50.

United Therapeutics Stock Performance

UTHR opened at $475.00 on Tuesday. The business’s 50-day simple moving average is $487.22 and its 200 day simple moving average is $423.14. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The firm has a market capitalization of $20.45 billion, a PE ratio of 18.00, a PEG ratio of 2.50 and a beta of 0.85.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $470.43, for a total value of $10,584,675.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders sold 519,364 shares of company stock worth $248,945,392. 10.30% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.